Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus VIVLODEX.
JUNIOR STRENGTH IBUPROFEN vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category D/X
Category C
NSAID
NSAID